This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: AstraZeneca Acquires Amplimmune for $500M

Stocks in this article: AZN

NEW YORK ( TheStreet) -- London biopharmaceutical conglomerate AstraZaneca (AAPL) said Monday it agreed to acquire venture capital-backed cancer drug research company Amplimmune for up to $500 million.

Amplimmune becomes the second cancer drug developer to be acquired in less than 24 hours. On Sunday Amgen (AMGN), agreed to buy Onyx Pharmaceuticals (ONYX) for $10.4 billion. AstraZeneca had been mentioned as a possible bidder for Onyx after the target received a $10 billion unsolicited bid from Amgen in June and put itself on the auction block.

Under financial terms of the Amplimmune acquisition, AstraZeneca will pay $225 million upfront and up to another $275 million in earnouts if the target hits certain milestones.

Amplimmune's main AMP-514 cancer therapy drug candidate is currently in pre-clinical stages and the Gaithersburg, Md.-based company, founded in 2007, expects to take the drug candidate to clinical trials by year's end.

InterWest Partners and Wellcome Trust are Amplimmune backers. The two firms collectively invested about $20 million in Amplimmune in 2007.

"Both companies are passionate about developing new cancer therapies for patients and are excited about the potential of immunotherapies," said Amplimmune CEO Michael Richman in a statement.

AstraZeneca will make the acquisition through its MedImmune subsidiary.

The Amplimmune deal is the latest in what has been an active M&A year for AstraZeneca as it looks to restock its drug pipeline that has been hurt by upcoming expiring patents, including one for its Nexium heartburn medicine, which is set to expire in mid 2014.

In June, AstraZeneca acquired pulmonary disease treatment firm Pearl Therapeutics for up to $1.15 billion. One month earlier, it paid $443 million for Omthera Pharmaceuticals, a blood disease researcher.

The Amplimmune transaction is expected to close by the end of the third quarter, pending regulatory approval.

AstraZeneca shares traded 10 cents lower, to $50.58, on Monday afternoon with its market capitalization near $63 billion.

Neither AstraZeneca nor Amplimmune returned calls on Monday.

-- Written by Demitri Diakantonis in New York

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs